Form 8-K - Current report

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 26, 2023

THERALINK TECHNOLOGIES, INC.

(Exact name of registrant as specified in its charter)

Nevada	000-52218	20-2590810
(State or other jurisdiction	(Commission	(I.R.S. Employer
of incorporation)	File Number)	Identification No.)

15000 W. 6th Ave., #400

Golden, CO 80401

(Address of principal executive offices)

(888) 585-4923

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: None

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Theralink Technologies, Inc. (the “Company”) announces that Faith Zaslavsky, age 48, has been appointed Chief Executive Officer of the Company effective June 26, 2023. Ms. Zaslavsky has served as the Company’s President and Chief Operating Officer since December 2022.

Ms. Zaslavsky has over 23 years of experience in the field of genomics and multiple commercialization successes to her credit. She has made significant contributions to the development of new genomic offerings and the application of genomics to clinical practice, ultimately making genomics more accessible to patients and healthcare providers while building corporate value. Amongst other successes, Ms. Zaslavsky has been instrumental in the commercialization of tests that detect mutations in BRCA1 and BRCA2 genes associated with increased risk of breast and ovarian cancer; provided oversight for tests used to detect mutations in genes associated with Lynch syndrome, a hereditary cancer syndrome; and launched an oncology suite of solutions providing guidance in therapeutic decision making. Cumulatively, these tests inform thousands of physicians, and help treat or prevent countless cases of cancer. Ms. Zaslavsky received a bachelor’s degree in Business Administration from Washington State University in 1997.

Ms. Zaslavsky entered into an Offer Letter with the Company on December 5, 2022, which remains in place following her new appointment.

The Company’s former Chief Executive Officer, Mick Ruxin, M.D. has transitioned to become the Company’s Chief Medical Officer.

Item 7.01 Regulation FD Disclosure.

On June 27, 2023, the Company issued a press release announcing Ms. Zaslavsky’s appointment, which is attached to this Current Report on Form 8-K as Exhibit 99.1 and incorporated herein by reference.

This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01.

Financial Statements and Exhibits.

99.1		Press Release, dated June 27, 2023, issued by Theralink

104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	THERALINK TECHNOLOGIES, INC.

	By:	/s/ Faith Zaslavsky
	Name:	Faith Zaslavsky
	Title:	Chief Executive Officer

Date: June 29, 2023

Exhibit 99.1

Theralink Technologies Appoints Faith Zaslavsky as Chief Executive Officer

Golden, Colorado, June 27, 2023 (GLOBE NEWSWIRE) — Theralink Technologies, Inc. (OTC: THER) (“Theralink” or the “Company”), a precision oncology company with a novel phosphoprotein and protein assay for breast cancer in the process of merging with IMAC Holdings, Inc. (NASDAQ: BACK), today announces the appointment of Faith Zaslavsky as its new Chief Executive Officer. Ms. Zaslavsky, who has served as the Company’s President and Chief Operating Officer since December 2022, will assume this role effective June 26, 2023, replacing Mick Ruxin, M.D., who will transition to Theralink’s Chief Medical Officer.

“I am very excited to hand the reins to Faith as we take the strategic step to merge with IMAC,” commented Dr. Ruxin. “As we begin a new chapter of shifting our focus from research and development to commercialization for the Company, Faith checks all the boxes as an excellent fit for our future. She is a highly accomplished executive having previously served as president and general manager of the oncology business unit of a $2 billion dollar genetics company. A respected executive with a passion for health care innovation, Faith has unparalleled leadership ability and knowledge of international business, which will be instrumental as we move forward to help save lives with the Theralink assay for a spectrum of cancers.”

As Chief Executive Officer of Theralink, Ms. Zaslavsky will be tasked with leveraging her prior successes to spearhead commercialization of the Theralink^® Reverse Phase Protein Array assays, a next generation of genomic technology used to guide personalized cancer therapeutics.

Faith Zaslavsky stated, “On behalf of our executive leadership team, I want to thank Mick for his innumerable contributions and dedicated years of service to Theralink. Since his appointment to CEO in 2018, Mick has led the Theralink team through critical product development and business model transformations, which has enabled the Company to expand our product and intellectual property portfolio. I am honored to follow in his footsteps and embrace the opportunity to lead Theralink as we bring proprietary, life-changing testing solutions to physicians and patients facing a cancer journey.”

About Theralink Technologies, Inc.

Theralink Technologies is a proteomics-based, precision medicine company with a nationally CLIA-certified and CAP-accredited laboratory located in Golden, Colorado. Through its unique and patented phosphoprotein and protein biomarker platform and laboratory developed tests (LDTs), Theralink’s technology targets multiple areas of oncology and drug development. In addition to the Company’s first assay for advanced breast cancer, Theralink is actively working on a second assay that is planned to be pan-tumor for solid tumors across multiple tumor types such as ovarian, endometrial, pancreatic, liver, head and neck, colorectal, lung, prostate, among others. Theralink provides precision oncology data through its powerful Theralink^® Reverse Phase Protein Array assays to assist the biopharmaceutical industry and clinical oncologists in identifying likely responders and non-responders to both FDA-approved and investigational drug treatments. Theralink intends to help improve cancer outcomes for patients, help reveal therapeutic options for oncologists, and support biopharmaceutical drug development by using a beyond-genomics approach to molecular profiling that directly measures drug target levels and activity. For more information, please visit www.theralink.com.

Contact:
Al kucharchuk
Al.Kucharchuk@theralink.com

Cover	Jun. 26, 2023
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Jun. 26, 2023
Entity File Number	000-52218
Entity Registrant Name	THERALINK TECHNOLOGIES, INC.
Entity Central Index Key	0001362703
Entity Tax Identification Number	20-2590810
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	15000 W. 6th Ave.
Entity Address, Address Line Two	#400
Entity Address, City or Town	Golden
Entity Address, State or Province	CO
Entity Address, Postal Zip Code	80401
City Area Code	(888)
Local Phone Number	585-4923
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Entity Emerging Growth Company	false